Earnings results for Millendo Therapeutics (NASDAQ:MLND)
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.5 and remained the same over the past month at -0.5. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -2.11 and remained the same over the past month at -2.11 . none raised and none lowered their forecast.
Millendo Therapeutics last issued its earnings data on May 8th, 2020. The reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.02. Millendo Therapeutics has generated ($3.25) earnings per share over the last year. Millendo Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 10th, 2020 based off prior year’s report dates.
Analyst Opinion on Millendo Therapeutics (NASDAQ:MLND)
6 Wall Street analysts have issued ratings and price targets for Millendo Therapeutics in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 290.63%. The high price target for MLND is $22.00 and the low price target for MLND is $2.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Millendo Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $7.50, Millendo Therapeutics has a potential upside of 290.6% from its current price of $1.92. Millendo Therapeutics has only been the subject of 4 research reports in the past 90 days.
Dividend Strength: Millendo Therapeutics (NASDAQ:MLND)
Millendo Therapeutics does not currently pay a dividend. Millendo Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Millendo Therapeutics (NASDAQ:MLND)
In the past three months, Millendo Therapeutics insiders have not sold or bought any company stock. Only 3.70% of the stock of Millendo Therapeutics is held by insiders. 66.40% of the stock of Millendo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Millendo Therapeutics (NASDAQ:MLND
Earnings for Millendo Therapeutics are expected to grow in the coming year, from ($2.11) to ($1.36) per share. The P/E ratio of Millendo Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Millendo Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Millendo Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
More latest stories: here